Biotechnology · Nasdaq

ONCBeOne Medicines Ltd.

Last close
$416.54 +0.1%
52-week range
$253.95 to $424.73
Market cap
$619B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$5.34B
+40% vs FY24
Net income
$287M
+144% vs FY24
Free cash flow
$942M
+249% vs FY24
Net cash
$3.52B
Cash $4.55B, debt $1.03B

Stock price

+1,431% since Dec 2016

Valuation vs its own 10 years

Below its 10-year median on 1 multiple

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
689x
n/a: Not enough history
Price / sales
93.6x
62.7x48,109x
23rd percentile, below its median of 222x
EV / EBITDA
452x
n/a: Not enough history
Price / free cash flow
427x
n/a: Not enough history

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
689x
Earnings yield
0.1%
Price / sales
93.6x
Price / book
106x
Price / operating cash flow
389x
EV / EBITDA
452x
EV / sales
92.9x
Free cash flow yield
0.2%

Profitability

Gross margin
89.4%
Operating margin
17.8%
Net margin
13.9%
Return on equity
15.7%
Return on capital
13.6%

Growth per year

Revenue, 3 years
+55.7%
Revenue, 5 years
+76.8%
Revenue, 9 years
+158%
EPS, 3 years
n/aNot meaningful (a loss in the window)

Balance sheet

Cash and investments
$5.78B
Total debt
$1.20B
Net cash
$4.58B
Debt / equity
0.21x
Current ratio
3.55x

Shares and dividend

Shares outstanding
1.48B
Share count, 5 years
+35.9%
Beta, 1 year
0.69
Dividend yield
n/a
Dividend per share, TTM
n/a
Payout ratio
n/a

n/a: No dividend

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $1.89B
RevenueNet income
Gross profitLatest quarter $1.67B
EBITDALatest quarter $480M
Margins89 / 22 / 20%
GrossOperatingNet
Earnings per shareLatest quarter $0.25
Cash flowLatest quarter $509M
OperatingCapexFree
Cash vs debtLatest quarter $5.78B
Cash and investmentsTotal debt
P/E historyNow 689x
P/E
P/S historyNow 93.6x
P/S, median 222x dashed

Where the revenue comes from

Collaboration went from 11% to 1% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

ProductCollaboration
FY22
89%11%
$1.42B
FY23
89%11%
$2.46B
FY24
99%
$3.81B
FY25
99%
$5.34B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Product$5.28B98.9%+40%
Collaboration$61.0M1.1%+99%

Biotechnology peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
ONC BeOne Medicines Ltd. $619B +33% 17.8%689x93.6x Not enough history
ABBV AbbVie Inc. $521B +11% 32.2%50.8x7.9x 72nd percentile
AMGN Amgen Inc $252B +8% 32.4%27.0x6.5x 78th percentile
GILD Gilead Sciences, Inc. $208B +7% -7.6%No earnings6.7x No earnings
VRTX Vertex Pharmaceuticals Inc / Ma $137B +10% 33.2%34.7x10.5x 71st percentile
MRNA Moderna, Inc. $90.4B +13% -116%No earnings35.8x No earnings

The company

Sector
Health Care
Industry
Biotechnology
Headquarters
Basel
Fiscal year ends
December

Around the numbers

What the rest of EdgeStacker knows about ONC.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 130 active funds. Crowd level: quiet.

Open the Smart money tab